Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

The FDA has rejected ITM Isotopes Technologies' drug ITM-11 for gastroenteropancreatic neuroendocrine tumors due to manufacturing and chemistry concerns, not clinical or safety data. ITM plans to address these issues and resubmit the drug application.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your drug's path to FDA approval just got sidetracked by manufacturing quality controls, not clinical evidence. Fixing third-party production now can reopen the US market and keep your pipeline viable.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-rejectionmanufacturing-issuesneuroendocrine-tumorsradiopharmadrug-development